Non Small Cell Lung Cancer Clinical Trials

202 studies are recruiting for non small cell lung cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Phoenix, Arizona

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

2. A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

   The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05837767 on ClinicalTrials.gov

3. First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

   Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutati…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   25 in total

   Run by

   Pierre Fabre Medicament

   See if you can join NCT06043817 on ClinicalTrials.gov

4. A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

   A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who h…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Miami, Coral Gables, Florida

   Locations

   11 in total

   Run by

   Ankyra Therapeutics, Inc

   See if you can join NCT07027514 on ClinicalTrials.gov

5. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

   This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC San Diego Moores Cancer Center, La Jolla, California

   Locations

   5 in total

   Run by

   Fate Therapeutics

   See if you can join NCT07216105 on ClinicalTrials.gov

6. Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

   Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments. Objective…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT02682667 on ClinicalTrials.gov

7. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

   Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Gilbert, Arizona

   Locations

   23 in total

   Run by

   AstraZeneca

   See if you can join NCT05877599 on ClinicalTrials.gov

8. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

   Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   St. Jude Medical Center, Fullerton, California

   Locations

   118 in total

   Run by

   ArriVent BioPharma, Inc.

   See if you can join NCT07185997 on ClinicalTrials.gov

9. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

   The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Alabama Oncology, Birmingham, Alabama

   Locations

   153 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06881784 on ClinicalTrials.gov

10. Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

    The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study detai…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Los Alamitos, California

    Locations

    167 in total

    Run by

    AstraZeneca

    See if you can join NCT06350097 on ClinicalTrials.gov

11. Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

    This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    8 in total

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06745882 on ClinicalTrials.gov

12. Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

    Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (N…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Palo Verde Hematology Oncology, Glendale, Arizona

    Locations

    158 in total

    Run by

    Nuvalent Inc.

    See if you can join NCT06765109 on ClinicalTrials.gov

13. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building, Irvine, California

    Locations

    186 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07100080 on ClinicalTrials.gov

14. Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

    This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Enloe Health Regional Cancer Center, Chico, California

    Locations

    4 in total

    Run by

    University of California, Davis

    See if you can join NCT07250477 on ClinicalTrials.gov

15. Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

    Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs…

    Stage

    Phase 2

    Ages

    18 to 72

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT03412877 on ClinicalTrials.gov

16. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

    This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival ass…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Jiangxi Cancer Hospital, Nanchang, Jiangxi

    Locations

    260 in total

    Run by

    Summit Therapeutics

    See if you can join NCT05899608 on ClinicalTrials.gov

17. Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

    Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Duarte, California

    Locations

    18 in total

    Run by

    AstraZeneca

    See if you can join NCT06218914 on ClinicalTrials.gov

18. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

    The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    52 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06586515 on ClinicalTrials.gov

19. A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

    A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Florida Cancer Specialists & Research Institute - Sarasota, Sarasota, Florida

    Locations

    3 in total

    Run by

    Blueprint Medicines Corporation

    See if you can join NCT07629960 on ClinicalTrials.gov

20. Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

    The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combina…

    Stage

    Phase 2

    Ages

    18 to 95

    Site

    Research Site, Little Rock, Arkansas

    Locations

    97 in total

    Run by

    AstraZeneca

    See if you can join NCT05061550 on ClinicalTrials.gov

21. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

    The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that int…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Alaska Oncology and Hematology ( Site 0039), Anchorage, Alaska

    Locations

    229 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06077760 on ClinicalTrials.gov

22. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hoag Family Cancer Institute, Newport Beach, California

    Locations

    14 in total

    Run by

    NextCure, Inc.

    See if you can join NCT06774963 on ClinicalTrials.gov

23. BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

    This single-arm phase 2 study will enroll patients with resectable and operable stage IB - III non-small cell lung cancer and treat them with pre-operative ipilimumab + nivolumab plus low-dose stereotactic body radiation therapy (SBRT) delivered concurrently. Only patients who proceed to surgery wi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Rhode Island Hospital, Providence, Rhode Island

    Run by

    Brown University

    See if you can join NCT04933903 on ClinicalTrials.gov

24. A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

    To learn if SAR445877 can help to control locally advanced or metastatic NSCLC in patients who have previously received ICI therapy.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07133425 on ClinicalTrials.gov

25. Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

    The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Florida Clinical Trials Group, LLC, Plantation, Florida

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT07777822 on ClinicalTrials.gov